Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition von Burger, Jan A., Landau, Dan A., Taylor-Weiner, Amaro, Bozic, Ivana, Zhang, Huidan, Sarosiek, Kristopher, Wang, Lili, Stewart, Chip, Fan, Jean, Hoellenriegel, Julia, Sivina, Mariela, Dubuc, Adrian M., Fraser, Cameron, Han, Yulong, Li, Shuqiang, Livak, Kenneth J., Zou, Lihua, Wan, Youzhong, Konoplev, Sergej, Sougnez, Carrie, Brown, Jennifer R., Abruzzo, Lynne V., Carter, Scott L., Keating, Michael J., Davids, Matthew S., Wierda, William G., Cibulskis, Kristian, Zenz, Thorsten, Werner, Lillian, Cin, Paola Dal, Kharchencko, Peter, Neuberg, Donna, Kantarjian, Hagop, Lander, Eric, Gabriel, Stacey, O’Brien, Susan, Letai, Anthony, Weitz, David A., Nowak, Martin A., Getz, Gad, Wu, Catherine J.

Volltext

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia von Thompson, Philip A., Tam, Constantine S., O'Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.

Volltext

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo von Ponader, Sabine, Chen, Shih-Shih, Buggy, Joseph J., Balakrishnan, Kumudha, Gandhi, Varsha, Wierda, William G., Keating, Michael J., O'Brien, Susan, Chiorazzi, Nicholas, Burger, Jan A.

Volltext

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL von Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.

Volltext

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States von Chen, Qiushi, Jain, Nitin, Ayer, Turgay, Wierda, William G, Flowers, Christopher R, O'Brien, Susan M, Keating, Michael J, Kantarjian, Hagop M, Chhatwal, Jagpreet

Volltext

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors von Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A, Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N, Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J, Rezvani, Katayoun

Volltext

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia von Cervantes-Gomez, Fabiola, Lamothe, Betty, Woyach, Jennifer A, Wierda, William G, Keating, Michael J, Balakrishnan, Kumudha, Gandhi, Varsha

Volltext

Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs von Londin, Eric, Loher, Phillipe, Telonis, Aristeidis G., Quann, Kevin, Clark, Peter, Jing, Yi, Hatzimichael, Eleftheria, Kirino, Yohei, Honda, Shozo, Lally, Michelle, Ramratnam, Bharat, Comstock, Clay E. S., Knudsen, Karen E., Gomella, Leonard, Spaeth, George L., Hark, Lisa, Katz, L. Jay, Witkiewicz, Agnieszka, Rostami, Abdolmohamad, Jimenez, Sergio A., Hollingsworth, Michael A., Yeh, Jen Jen, Shaw, Chad A., McKenzie, Steven E., Bray, Paul, Nelson, Peter T., Zupo, Simona, Van Roosbroeck, Katrien, Keating, Michael J., Calin, George A., Yeo, Charles, Jimbo, Masaya, Cozzitorto, Joseph, Brody, Jonathan R., Delgrosso, Kathleen, Mattick, John S., Fortina, Paolo, Rigoutsos, Isidore

Volltext

Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth von Cramer, Shira L, Saha, Achinto, Liu, Jinyun, Tadi, Surendar, Tiziani, Stefano, Yan, Wupeng, Triplett, Kendra, Lamb, Candice, Alters, Susan E, Rowlinson, Scott, Zhang, Yan Jessie, Keating, Michael J, Huang, Peng, DiGiovanni, John, Georgiou, George, Stone, Everett

Volltext

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer In... von Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillaume, Döhner, Hartmut, Hillmen, Peter, Keating, Michael J., Montserrat, Emili, Rai, Kanti R., Kipps, Thomas J.

Volltext

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia von Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O'Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, Keating, Michael J.

Volltext

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study von Burger, Jan A, Dr, Keating, Michael J, Prof, Wierda, William G, Prof, Hartmann, Elena, MD, Hoellenriegel, Julia, MS, Rosin, Nathalie Y, PhD, de Weerdt, Iris, MD, Jeyakumar, Ghayathri, MD, Ferrajoli, Alessandra, MD, Cardenas-Turanzas, Marylou, PhD, Lerner, Susan, MS, Jorgensen, Jeffrey L, MD, Nogueras-González, Graciela M, MS, Zacharian, Gracy, MS, Huang, Xuelin, PhD, Kantarjian, Hagop, Prof, Garg, Naveen, MD, Rosenwald, Andreas, Prof, O'Brien, Susan, Prof

Volltext

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia von Hoellenriegel, Julia, Meadows, Sarah A., Sivina, Mariela, Wierda, William G., Kantarjian, Hagop, Keating, Michael J., Giese, Neill, O'Brien, Susan, Yu, Albert, Miller, Langdon L., Lannutti, Brian J., Burger, Jan A.

Volltext

Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy von Lu, Weiqin, Hu, Yumin, Chen, Gang, Chen, Zhao, Zhang, Hui, Wang, Feng, Feng, Li, Pelicano, Helene, Wang, Hua, Keating, Michael J, Liu, Jinsong, McKeehan, Wallace, Wang, Huamin, Luo, Yongde, Huang, Peng

Volltext

Toward the potential cure of leukemias in the next decade von Kantarjian, Hagop M., Keating, Michael J., Freireich, Emil J

Volltext

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia von Tam, Constantine S., O'Brien, Susan, Wierda, William, Kantarjian, Hagop, Wen, Sijin, Do, Kim-Anh, Thomas, Deborah A., Cortes, Jorge, Lerner, Susan, Keating, Michael J.

Volltext

Ibrutinib and Venetoclax for First-Line Treatment of CLL von Jain, Nitin, Keating, Michael, Thompson, Philip, Ferrajoli, Alessandra, Burger, Jan, Borthakur, Gautam, Takahashi, Koichi, Estrov, Zeev, Fowler, Nathan, Kadia, Tapan, Konopleva, Marina, Alvarado, Yesid, Yilmaz, Musa, DiNardo, Courtney, Bose, Prithviraj, Ohanian, Maro, Pemmaraju, Naveen, Jabbour, Elias, Sasaki, Koji, Kanagal-Shamanna, Rashmi, Patel, Keyur, Jorgensen, Jeffrey, Garg, Naveen, Wang, Xuemei, Sondermann, Katrina, Cruz, Nichole, Wei, Chongjuan, Ayala, Ana, Plunkett, William, Kantarjian, Hagop, Gandhi, Varsha, Wierda, William

Volltext

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells von Patel, Viralkumar, Balakrishnan, Kumudha, Bibikova, Elena, Ayres, Mary, Keating, Michael J, Wierda, William G, Gandhi, Varsha

Volltext

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling von McMullen, Julie R., Boey, Esther J.H., Ooi, Jenny Y.Y., Seymour, John F., Keating, Michael J., Tam, Constantine S.

Volltext

Can the Anglo-Scottish Union Survive Brexit? von Keating, Michael

Volltext